The MS Trust is delighted that Vumerity (diroximel fumarate) has been approved by NICE (National Institute for Health and Care Excellence) for people with active relapsing remitting multiple sclerosis.
NICE has recommended that Vumerity can be prescribed for people with relapsing remitting MS who are having relapses or have MRI evidence of MS activity.
This is excellent news. Vumerity is as effective as Tecfidera but has fewer stomach problems, meaning you can take it with a meal or on an empty stomach. An effective treatment that fits into your daily routines means you can live a life with MS that is not defined by MS.
- David Martin, Chief Executive Officer, MS Trust
Vumerity (diroximel fumarate) is taken as a tablet, twice daily. You start with a low dose for the first week then increase to the full dose. This gives your body time to get used to the new treatment, reducing the risk of side effects.
Vumerity is similar to Tecfidera. In the body, both drugs are converted to monomethyl fumarate which reduces inflammation caused by MS activity and may protect nerve cells from damage.
In clinical trials, Vumerity reduced relapse rates and the number of active lesions seen on MRI scans.
The most common side effects reported in clinical trials were gastrointestinal discomfort and flushing. People taking Vumerity experienced fewer days of gastrointestinal symptoms, took less medication for gastrointestinal symptoms and missed less work compared to Tecfidera. Participants who stopped treatment because of gastrointestinal problems was 0.8% for Vumerity and 4.8% for Tecfidera.
Other side effects included nasopharyngitis (common cold), diarrhoea and chest infections.
The ADAMS project
25/05/2022 - 00:00
Dr Benjamin Jacobs spoke to us about a new study on the genetics of MS in people from minority ethnic backgrounds which may eventually shed light on why MS can be more severe for Black and Asian people.
Is a ketogenic diet good for people with multiple sclerosis?
18/05/2022 - 00:00
Researchers assessed whether a ketogenic diet, low in carbohydrates and high in fats, is suitable for people with multiple sclerosis.
Mayzent (siponimod) use expanded in England for secondary progressive multiple sclerosis
03/05/2022 - 00:00
NHS England has agreed that Mayzent can be prescribed for people with active secondary progressive multiple sclerosis whose disability has increased for at least 6 months, unrelated to relapses, and while taking a disease modifying drug.
Sign up for updates from us
Keep up-to-date with the latest MS news, explore new research, read the stories of people living with MS, find out practical tips from MS experts, and discover exciting fundraising opportunities.